中恒集团：5月7日召开业绩说明会，投资者参与

Core Viewpoint - 中恒集团 is focusing on enhancing its market strategies and expanding its product offerings in both the pharmaceutical and health sectors, while also exploring potential mergers and acquisitions to strengthen its position in the industry [1][2][5]. Group 1: Business Strategies - The company is implementing personalized market strategies through regional collaboration, focusing on key products like 血栓通 and 中华跌打丸 to expand its marketing and sales efforts [2]. - It aims to deepen its market penetration by developing specialized marketing teams and establishing sales channels that radiate from provincial capitals to surrounding areas [2]. - The company is leveraging new media and exhibitions to enhance brand visibility and expand its sales network [2]. Group 2: Product Development - 中恒集团 has launched 154 new health products in 2024, with 51 already in production, while continuing to promote its traditional product, 双钱龟苓膏 [3]. - The company is focusing on core health food products and expanding its sales channels to achieve growth in both pharmaceutical and health food sectors [4]. Group 3: Growth Opportunities - The company identifies several growth points, including expanding its blood thrombus product market, enhancing the coverage of its跌打丸 product, and increasing e-commerce sales [4]. - It is also innovating in the daily chemical sector and exploring international markets, particularly in Southeast Asia, through partnerships [4]. Group 4: Financial Performance - In Q1 2025, 中恒集团 reported a revenue of 742 million yuan, a year-on-year decrease of 7.92%, and a net profit of 18.27 million yuan, down 66.61% [7]. - The company's debt ratio stands at 31.89%, with a gross profit margin of 29.62% [7]. Group 5: Share Buyback - The company plans to conduct a share buyback within a range of 300 million to 500 million yuan, with the first buyback executed on April 10, 2025, totaling approximately 42.15 million shares [6].